Y-mAbs Therapeutics 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Mike Rossi
최고 경영자
US$3.1m
총 보상
| CEO 급여 비율 | 3.5% |
| CEO 임기 | less than a year |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 3.6yrs |
| 이사회 평균 재임 기간 | 7yrs |
최근 관리 업데이트
Recent updates
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Nov 19
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 12Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$25m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$3m | US$110k | -US$21m |
보상 대 시장: Mike 의 총 보상 ($USD 3.11M )은 US 시장( $USD 2.24M ).
보상과 수익: Mike 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Mike Rossi (53 yo)
less than a year
테뉴어
US$3,110,553
보상
Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.11m | 데이터 없음 | |
| Founder | 9.6yrs | US$2.45m | 0.58% $ 2.7m | |
| Senior VP & Chief Commercial Officer | 2.8yrs | US$887.28k | 0.0095% $ 44.8k | |
| CFO & Treasurer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & COO | 7yrs | 데이터 없음 | 0.0021% $ 9.9k | |
| Senior VP & CTO | 8.8yrs | 데이터 없음 | 0.12% $ 543.8k | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Medical Officer | 4.4yrs | US$724.92k | 0.019% $ 89.5k | |
| Chief Development Officer | less than a year | 데이터 없음 | 데이터 없음 |
3.6yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 관리: YMAB 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.11m | 데이터 없음 | |
| Founder | 9.6yrs | US$2.45m | 0.58% $ 2.7m | |
| Independent Chairman of the Board | 7yrs | US$184.31k | 0.063% $ 296.3k | |
| Independent Director | 6.9yrs | US$180.56k | 0.0052% $ 24.5k | |
| Director | less than a year | 데이터 없음 | 0% $ 0 | |
| Independent Director | 9.2yrs | US$158.06k | 0.0052% $ 24.5k | |
| Independent Director | 7yrs | US$158.06k | 0.0052% $ 24.5k | |
| Independent Director | 4.4yrs | US$168.06k | 0.0052% $ 24.5k |
7.0yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 이사회: YMAB 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.